OBJECTIVE: To assess whether three health-related quality-of-life (HRQL) measures (the EQ-5Dindex, SF-6D, and EQ VAS) can discriminate between the HRQL of different groups of individuals. METHODS: In one UK general practice a cross-sectional survey requested information on six sociodemographic factors, 10 clinical conditions, and the three HRQL measures. Regression analyses were used to assess whether there was a significant difference in HRQL between groups with different sociodemographic factors and those with and without clinical conditions. RESULTS: One thousand eight hundred and sixty-five questionnaires were returned. There was a significant difference between the HRQL of the majority of different groups according to each HRQL measure. However, not all of the measures could discriminate between groups of different ethnicity, gender, or smoking status, or those with and without asthma, stroke, cancer or diabetes. CONCLUSION: The HRQL of the majority of different groups could be discriminated between by the EQ-5Dindex, SF-6D, and EQ VAS.
OBJECTIVE: To assess whether three health-related quality-of-life (HRQL) measures (the EQ-5Dindex, SF-6D, and EQ VAS) can discriminate between the HRQL of different groups of individuals. METHODS: In one UK general practice a cross-sectional survey requested information on six sociodemographic factors, 10 clinical conditions, and the three HRQL measures. Regression analyses were used to assess whether there was a significant difference in HRQL between groups with different sociodemographic factors and those with and without clinical conditions. RESULTS: One thousand eight hundred and sixty-five questionnaires were returned. There was a significant difference between the HRQL of the majority of different groups according to each HRQL measure. However, not all of the measures could discriminate between groups of different ethnicity, gender, or smoking status, or those with and without asthma, stroke, cancer or diabetes. CONCLUSION: The HRQL of the majority of different groups could be discriminated between by the EQ-5Dindex, SF-6D, and EQ VAS.
Authors: Martina Garau; Koonal K Shah; Anne R Mason; Qing Wang; Adrian Towse; Michael F Drummond Journal: Pharmacoeconomics Date: 2011-08 Impact factor: 4.981
Authors: Shannon Pike; Anne Cusick; Kylie Wales; Lisa Cameron; Lynne Turner-Stokes; Stephen Ashford; Natasha A Lannin Journal: PLoS One Date: 2021-02-11 Impact factor: 3.240
Authors: Roisin Adams; Benjamin M Craig; Cathal D Walsh; Douglas J Veale; Barry Bresnihan; Oliver FitzGerald; Michael Barry Journal: Value Health Date: 2011-07-08 Impact factor: 5.725
Authors: Garry R Barton; Tracey H Sach; Anthony J Avery; Michael Doherty; Claire Jenkinson; Kenneth R Muir Journal: Cost Eff Resour Alloc Date: 2009-07-17